Citation Impact
Citing Papers
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
2009
Epigenetic Resensitization to Platinum in Ovarian Cancer
2012
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
2009 StandoutScience
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
2006
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
2012
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Cytosine methylation regulates oviposition in the pathogenic blood fluke Schistosoma mansoni
2011 Standout
Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice
2014
A prognostic score for patients with lower risk myelodysplastic syndrome
2007
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity
2010 StandoutNobel
DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes
2008
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
2007
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
2008
Acute Myeloid Leukemia in the Elderly
2008
Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
2006
Decitabine and its role in the treatment of hematopoietic malignancies
2007
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Azacitidine
2005
Epigenetics in Cancer
2008 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Acute myeloid leukaemia
2006
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
2007
Epigenetics in cancer
2009 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
How were new medicines discovered?
2011 Standout
Decitabine—Bedside to bench
2006
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Azacitidine
2005
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
2008 Standout
DNA methylation-based biomarkers and the epigenetic clock theory of ageing
2018 Standout
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
2012
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia
2012
Therapy with azanucleosides for myelodysplastic syndromes
2010
Treatment of Acute Lymphoblastic Leukaemia
2007
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
2017
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Epigenetic regulation of hematopoietic stem cell aging
2014
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
2005
TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia
2012
The future of epigenetic therapy in solid tumours—lessons from the past
2013
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
2007
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
2006 Standout
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
2006
A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer
2006
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
2005
Acute Myeloid Leukemia
2015 Standout
Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure
2005
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
2014
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
2007
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
2009
Loss of TET proteins in regulatory T cells promotes abnormal proliferation, Foxp3 destabilization and IL-17 expression
2019 StandoutNobel
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
2006
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
2006
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
2003
Combination therapy in combating cancer
2017 Standout
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
2007 Standout
Exosomes as drug delivery vehicles for Parkinson's disease therapy
2015 Standout
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Molecular targets of dietary agents for prevention and therapy of cancer
2006 Standout
Multiple Myeloma
2011 Standout
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Cancer Epigenetics: Modifications, Screening, and Therapy
2007
Works of Jan Davis being referenced
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
2006
Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.
2005
Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules
2005
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
2002
Decitabine Low-Dose Schedule (100 mg/m2/course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.
2004
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
2003